Background: The most common treatment for patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) is sorafenib which offers a median survival of w11 months. Previous studies have shown a potential survival benefit of liver resection (LR) for patients with MVI but this approach is still controversial. The aim of this study was to assess the postoperative and long-term outcomes after LR of patients with HCC with MVI identified preoperatively. Methods: We included all patients diagnosed with HCC with the presence of MVI that were resected between January 2000 and August 2016. Preoperative MVI was defined as enhancing venous thrombus and/or tumoral direct invasion of portal or hepatic veins in any imaging before LR. The primary outcome was overall survival. Survival probabilities were estimated by the KaplaneMeier method and predictors of mortality were estimated by multivariate Cox regression. p < 0.05 was considered statistically significant. Results: 40 patients with HCC and MVI underwent LR. Table 1 shows the demographic and clinical characteristics. In all patients the preoperative MVI was confirmed in the path report. Complications 3a occurred in 12 (30%) patients. HCC recurrence occurred in 25 (60%) patients. The median recurrence-free survival was 5 months. The median overall survival was 29 months after LR. The 1-, 3-and 5years actuarial survival was 62%, 37% and 30% respectively. After adjustments for potential confounders, AFP>400 ng/mL [HR 4.8 (95% CI 1.5 e 16)] and portal vein invasion on preoperative imaging [HR 6 (95% CI 1.4 e 25.5)] were independent predictors of mortality. Conclusion: LR for patients with HCC and MVI is associated with high incidence of postoperative complications. Acceptable 5-years survival may be achieved after LR for patients with HCC and MVI. HPB 2018, 20 (S1), S36eS110
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